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Introduction
Cardiovascular disease (CVD), including ischaemic
coronary heart disease (CHD), stroke and periph-
eral vascular disease, is the leading cause of death
in the United States (1). More than 1 million
Americans die each year from myocardial infarction
(MI) and other forms of CHD (1). Various
national scientiﬁc guidelines recommend speciﬁc
pharmacotherapies for the treatment and prevention
of CVD (2–4).
The American Heart Association (AHA)⁄American
College of Cardiology (ACC) guidelines (2) for sec-
ondary prevention in patients with coronary and
other atherosclerotic vascular disease recommended
the following therapies: (i) angiotensin-converting
enzyme inhibitor (ACEI) for all patients with CVD
and ejection fraction < 40% and those with hyper-
tension, diabetes or chronic kidney disease, unless
contraindicated, (ii) angiotensin II receptor blocker
(ARB) for those intolerant of ACEIs and who have
heart failure or MI with ejection fraction £ 40%, (iii)
beta-blocker for those who have MI or acute coro-
nary syndrome, (iv) antiplatelet or anticoagulant
therapy for those who have acute coronary syn-
drome, percutaneous coronary intervention, or MI,
and aspirin for all patients unless contraindicated,
and (v) lipid-lowering drug therapy if low-density
lipoprotein cholesterol (LDL-C) is ‡ 100 mg⁄dl. The
AHA 2004 guidelines for CVD prevention in women,
additionally recommended aspirin use for moderate-
and high-risk women (3). The National Cholesterol
Education Program Adult Treatment Panel III
(NCEP ATP III) guidelines recommend statin ther-
apy for individuals at high or moderate CHD risk if
their LDL-C is not at target goal (4).
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SUMMARY
Aims: Guidelines recommend antihypertensive, lipid-lowering and⁄or antiplatelet
therapy for prevention of cardiovascular disease (CVD). This study examined the
utilisation of cardiovascular therapies among individuals at CVD risk to assess
adherence to guidelines. Methods: Respondents to the SHIELD study were clas-
siﬁed based on National Cholesterol Education Program Adult Treatment Panel
III risk categories. High coronary heart disease (CHD) risk (n = 7510) was
deﬁned as self-reported diagnosis of heart disease⁄heart attack, narrow or
blocked arteries, stroke or diabetes; moderate risk (n = 4823) included respon-
dents with ‡ 2 risk factors (i.e., men > 45 years, women > 55 years, hyperten-
sion, low high-density lipoprotein cholesterol, smoking and family history of
CHD); and low risk (n = 5307) was 0–1 risk factor. Respondents reporting a
myocardial infarction, stroke or revascularisation at baseline (prior CVD event)
(n = 3777), those reporting a new CVD event during 2 years of follow up
(n = 953), and those with type 2 diabetes mellitus (n = 3937) were evaluated.
The proportion of respondents reporting treatment with lipid-lowering, antiplatelet
or antihypertensive agents was calculated. Results: Utilisation of lipid-lowering
therapy was low (£ 25%) in each group. Prescription antithrombotic therapy was
minimal among respondents with prior CVD events, but 47% received antihyper-
tensive medication. No use before or after a new CVD event was reported by 36%
of respondents for lipid-lowering, 32% for antithrombotic and > 50% for antihyper-
tensive medications. Conclusions: More than 50% of at-risk respondents and
> 33% of respondents with new CVD events were not taking CVD therapy as
recommended by guidelines.
What’s known
Cardiovascular disease is a prevalent condition that
is the leading cause of death in the United States
and several national guidelines provide
recommendations for the treatment and prevention
of cardiovascular disease in routine clinical practice.
What’s new
This study highlights the gap in the utilisation of
cardiovascular drug therapies, including statins,
antiplatelet ⁄anticoagulant and anti-hypertensive
agents among respondents with high and moderate
coronary heart disease risk and those with a prior
cardiovascular event or new incident event. The
ﬁndings indicate that the treatment guidelines have
not been translated into clinical practice for many
individuals at risk of cardiovascular disease.
Linked Comment: Connolly. Int J Clin Pract 2010; 64: 529–32.
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604 doi: 10.1111/j.1742-1241.2009.02258.xThe purpose of this study was to evaluate the util-
isation of prescription therapies and aspirin among a
large, community-based cohort of individuals at risk
for CVD, including those with type 2 diabetes mell-
itus (T2DM) or prior CVD events (MI, stroke), or
who experienced a new CVD event during follow up
to assess whether prescribing guidelines were being
adopted.
Methods
Individuals at risk for or with a prior history of
CVD events (i.e. MI, stroke or revascularisation)
were identiﬁed from the Study to Help Improve
Early evaluation and management of risk factors
Leading to Diabetes (SHIELD). SHIELD is a popula-
tion-based survey conducted to better understand
the risk and disease burden of diabetes and CVD.
SHIELD included an initial screening phase to iden-
tify cases of interest in the general population and a
detailed baseline survey to follow up identiﬁed cases
for health status, health knowledge, attitudes, behav-
iours and treatment. Annual follow-up surveys were
administered to obtain information about changes in
health status, behaviours and treatment. A detailed
description of the SHIELD methodology has been
published previously (5,6).
In brief, the screening survey was mailed to a
stratiﬁed random sample of 200,000 US households,
representative of the US population for geographical
residence, household size and income and age of
head of household (7). The head of household pro-
vided responses for up to four adult (aged
‡ 18 years) household members, resulting in a
response rate of 63.7% (127,420 households for
211,097 adults). The baseline survey was sent to
22,001 selected individuals derived from the screen-
ing respondents. A response rate of 71.8% was
obtained (n = 15,794).
In August 2005, the ﬁrst annual follow-up survey
was mailed to all individuals selected for the baseline
survey who were still enrolled in the household panel
(n = 19,613). The second follow-up survey was
mailed in July 2006 to individuals who had returned
either or both the baseline and ﬁrst annual question-
naires (n = 18,445). The 2005 survey had a response
rate of 72%, and a 75% response rate was obtained
for the 2006 survey (n = 13,877). This study utilised
the baseline, 2005 and 2006 survey responses. De-
identiﬁed information was analysed in compliance
with the Health Insurance Portability and Account-
ability Act. SHIELD utilised a household consumer
panel, and as consumer panels are not considered
clinical studies, institutional review board approval
was not required.
Study population
Three primary respondent groups were identiﬁed
from the baseline survey: (i) high CHD risk, (ii)
moderate CHD risk, and (iii) low CHD risk. Sub-
group analyses of the high-risk group were also con-
structed for individuals who had T2DM and
individuals who had a prior history of CVD event.
An additional respondent group was identiﬁed as
those who completed the baseline survey and the
two follow-up surveys and had a new CVD event
during the 2-year follow up.
Coronary heart disease risk was deﬁned based on
NCEP ATP III risk categories using disease status
and risk factor counts (4,8). High CHD risk was
deﬁned as self-reported diagnosis of heart disease,
narrow or blocked arteries⁄carotid artery disease,
stroke or T2DM. For the high CHD risk group, two
subgroups were also deﬁned: (i) respondents with
T2DM who may also have CVD, and (ii) respon-
dents with major CVD events who may also have
T2DM. Moderate to moderately high CHD risk was
deﬁned as respondents reporting ‡ 2 of the following
risk factors: (i) men > 45 years or women > 55 years
of age, (ii) reported diagnosis of low high-density
lipoprotein cholesterol, (iii) reported diagnosis of
high blood pressure⁄hypertension, (iv) current smo-
ker and (v) family history of heart disease, narrow or
blocked arteries, stroke or diabetes. The lower CHD
risk group included respondents with 0–1 of the
above risk factors.
T2DM was deﬁned as a self-report of having been
‘told by a doctor, nurse, or other healthcare profes-
sional that you have type 2 diabetes.’ CVD event was
deﬁned as self-report of heart attack, stroke, heart
bypass surgery or angioplasty. If a CVD event was
reported at the baseline survey, then the respondent
was classiﬁed as having a prior CVD event. A new
CVD event was deﬁned as no CVD event reported at
baseline but a reported event during the 2 years of
annual follow-up surveys.
Therapy assessment
Respondents reported the name of each medication
currently prescribed to them. They were instructed
to refer to their medication labels for accurate
reporting. Lipid-lowering medications included
monotherapy and combination therapy of statins,
ﬁbric acid derivatives, bile acid sequestrants and cho-
lesterol absorption inhibitors. Prescription antiplate-
let and anticoagulant agents included clopidogrel,
ticlopidine, cilostazol, dipyridamole, warfarin and
low-molecular-weight heparins. For aspirin use,
respondents who indicated that they took aspirin
every day were considered daily users. Daily aspirin
use was examined separately as well as included with
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Antihypertensive medications included ACEIs, ARBs
and beta-blockers. Diuretics and calcium channel
blockers were not included in the analysis of antihy-
pertensive medications because they are prescribed
for several different conditions.
Statistical analyses
Cross-sectional analysis of CVD medication use
(yes⁄no) was conducted for the baseline respondents.
Longitudinal analysis of CVD medication use among
respondents with a new CVD event during 2 years of
follow up was conducted for those respondents who
completed the baseline survey and the two follow-up
surveys. The proportion of respondents with a new
CVD event who reported drug treatment was com-
puted for: (i) use before and after CVD event, (ii)
use after event only, (iii) use before event only, and
(iv) no use before or after event. Bivariate analyses
included t-tests and v
2-tests for assessing differences
among groups. Logistic regression analyses assessed
the likelihood of statin treatment among baseline
CHD risk groups, adjusting for age, gender and
geographical region. Statistical signiﬁcance was set
a priori at p < 0.05.
Results
Baseline utilisation
Among baseline survey respondents, 7510 were high
CHD risk, 4823 were moderate risk and 5307 were
low risk. Low-risk individuals were signiﬁcantly
younger and more likely to be women and had
higher education and income than the other groups
(p < 0.001) (Table 1).
Utilisation of statin and other lipid-lowering ther-
apy was very low in each group (Figure 1). Signiﬁ-
cantly more respondents in the high CHD risk group
were receiving statins or any lipid-lowering therapy
(including statins) compared with moderate-risk or
low-risk groups (p < 0.001).
After adjusting for age, gender and geographical
region, high CHD risk and moderate CHD risk
groups were signiﬁcantly more likely to have received
statin therapy than low-risk respondents (p < 0.001).
The high-risk group was four times more likely
[odds ratio (OR) = 4.60, 95% conﬁdence interval
(CI) = 3.54–5.97] and the moderate risk group was
three times more likely (OR = 3.13, 95% CI = 2.45–
3.99) to have received statin therapy.
High risk subgroups
Of the 7510 high CHD risk respondents, there were
3937 respondents who had T2DM (2827 had T2DM
Table 1 Demographic characteristics of SHIELD respondents by CHD risk group
Characteristics
High CHD risk
(n = 7510)
Moderate CHD
risk (n = 4823)
Low CHD risk
(n = 5307)
Age, years, mean 60.4 57.2 43.5*
Women, % 56 60 70*
Race, % white 86 88 88
Education, % with some college or higher 64 68 75*
Income, % ‡ $40,000⁄year 47 56 64*
Geographic region, %
Northeast 19 19 19
North Central 24 25 25
South Atlantic 20 20 18
South Central 18 16 16
Mountain 6 6 7
Paciﬁc 13 13 14
*p-value < 0.0001 across risk groups. CHD, coronary heart disease; SHIELD, Study to Help Improve Early evaluation and management
of risk factors Leading to Diabetes.
*
*
*†
*†
Figure 1 Proportion of SHIELD respondents taking
antidyslipidaemia medications. *p < 0.001 for comparison
with high-risk group; +p < 0.001 for comparison with
moderate-risk group
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prior major CVD event. Within the high-risk group,
signiﬁcantly more respondents with a prior CVD
event received lipid-lowering therapy (25.0%) than
respondents with T2DM (19.5%) (p = 0.02). Signiﬁ-
cantly more T2DM respondents were receiving lipid-
lowering therapy than moderate and low CHD risk
groups (p < 0.001).
In examining the use of antiplatelet and antihyper-
tensive therapy among respondents with a prior
CVD event, a small proportion of these respondents
were taking the drug therapies recommended in
the AHA⁄ACC guidelines for secondary prevention
(Figure 2). Approximately 66% of the respondents
reported daily aspirin use. For respondents who
reported having an MI or stroke at the baseline survey,
an additional 1.4% were taking prescription antiplat-
elet or anticoagulant therapy at the time of the survey.
Less than 50% of the prior CVD event group was
receiving antihypertensive or dyslipidaemia therapy.
After adjusting for age, gender and geographical
region, moderate and low CHD risk groups were sig-
niﬁcantly less likely to receive statin therapy than
T2DM respondents (p < 0.001). The moderate CHD
risk group was 28% less likely (OR = 0.72,
95%CI = 0.61–0.86) and the low-risk group was 79%
less likely (OR = 0.21, 95% CI = 0.16–0.27) to have
received statin therapy. The high CHD risk group
(OR = 2.1, 95% CI = 1.7–2.6) and prior CVD event
group (OR = 1.25, 95% CI = 1.1–1.5) were signiﬁ-
cantly more likely to receive statin therapy than
T2DM respondents, after adjusting for age, gender
and geographical region (p < 0.01).
Longitudinal utilisation
SHIELD respondents who completed the baseline
and two subsequent annual surveys (n = 9497) were
evaluated to determine the utilisation of CVD medi-
cations among those who had an incident CVD
event (MI, stroke or revascularisation) during the
ﬁrst 2 years of follow up. Examining this group
allowed for closer proximity of medication use to the
time of the CVD event occurrence. A total of 953
respondents (10%) reported a new CVD event over
the 2 years of follow up, 6% (n = 572) in the ﬁrst
year and 4% (n = 381) in the second year. Among
those who experienced an incident CVD event, 64%
were women and 85% white, with a mean age of
59.7 years; 65% had some college education or
higher and 31% had T2DM.
There were 1151 new CVD events among the 953
respondents; 198 individuals reported two new
events in the 2 years of follow up. MI was the most
frequent new CVD event (n = 650, 56.5% of events).
There were 342 (29.7%) angioplasty or heart bypass
surgeries and 159 (13.8%) strokes over the 2 years.
Approximately 36% of respondents with incident
CVD events reported not taking lipid-lowering ther-
apy before or after the CVD event. Thirty per cent of
incident CVD individuals started lipid-lowering ther-
apy after the event and 9% did not continue with
therapy after their event (Figure 3). Antiplatelet,
anticoagulant therapy or daily aspirin was not used
by 32% of respondents at any point before or after
the incident CVD event. An additional 20% of
respondents started antithrombotic therapy after
their CVD event, while 5% used such therapy only
before their incident CVD event. For antihyperten-
sive therapy, approximately 54% of respondents with
incident CVD events did not use an ACEI or ARB
before or after their CVD event, and utilisation did
not increase substantially after the event (15%).
Beta-blockers were not used by 56% of respondents
before or after their CVD event.
To assess whether speciﬁc guideline recommen-
dations were being adopted in clinical practice,
medication use was examined by CVD event type.
AHA⁄ACC guidelines recommended beta-blockers
for individuals with MI (2). About 50% of respon-
dents with a new MI (n = 650) did not take a beta-
Figure 2 Proportion of respondents with prior CVD event taking CVD medications. ACEI, angiotensin-converting enzyme
inhibitor; ARB, angiotensin II receptor blocker; CVD, cardiovascular disease
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used a beta-blocker before their MI (Figure 4).
Among new stroke respondents (n = 159), 45% were
using antiplatelet, anticoagulant or daily aspirin ther-
apy before and after their stroke (Figure 4). An addi-
tional 20% of new stroke respondents started
antithrombotic therapy after their stroke.
Discussion
AHA⁄ACC guidelines (2) recommend lipid-lowering
therapy for the prevention of CVD, yet 75% of
respondents with a prior MI or stroke, 80% of
T2DM respondents, and > 33% of respondents with
an incident CVD event report not receiving lipid-
lowering therapy. This gap in utilisation of lipid-low-
ering therapy also existed for high and moderate
CHD risk respondents who, by deﬁnition, have CHD
(high risk) or hypertension and other risk factors
(moderate risk). The guidelines also recommend
antiplatelet therapy for treatment and prevention of
MI and stroke. More than 50% of respondents with
a prior CVD event did not receive antiplatelet,
anticoagulant or antihypertensive therapy, as recom-
mended in the guidelines. Daily aspirin use was not
adopted as a preventive measure by 34% of respon-
dents with a prior CVD event. Additionally, 32% of
respondents with an incident CVD event did not
take an antiplatelet or anticoagulant agent or daily
aspirin, and > 50% did not take an antihypertensive
agent (i.e. ACEI, ARB, or beta-blocker) either before
or after their event. Preventive drug therapy for MI
(beta-blocker) was not taken by 50% of respondents
with an incident MI. Antithrombotic therapy utilisa-
tion was higher among respondents with incident
stroke, with 45% of respondents taking this therapy
before and after their stroke and another 20% start-
ing therapy after their stroke.
These ﬁndings indicate a gap in preventive care
for these at-risk groups. It is possible that the
guidelines have not been translated into practice.
Physicians may be unaware of the guideline recom-
mendations, or if aware, they may not have adopted
the recommendations for all of their at-risk patients.
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Figure 4 Utilisation of medications by event type among respondents with a new CVD event
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not to initiate or to stop drug therapy possibly
because they did not understand their risk and⁄or
the underlying disease process, or because they were
concerned about medication-related adverse effects.
With a large proportion of at-risk individuals not
receiving preventive drug therapy, these study ﬁnd-
ings are a call to action. Awareness of the guideline
recommendations must be raised among physicians
to increase their adoption. Individuals at risk, includ-
ing those with prior or incident CVD event, must be
motivated to adopt preventive measures recom-
mended by their physicians for reducing CVD.
This study has several limitations that should be
considered in interpreting the results. Respondents
were not asked the reason why they were taking aspi-
rin daily; thus, their aspirin use may have been
related to other chronic conditions such as arthritis
or headaches. Among respondents with a prior CVD
event at baseline, information on when the CVD
event occurred prior to the survey was not assessed.
Thus, individuals with an MI or stroke years ago
may have received antiplatelet or anticoagulant ther-
apy around the time of their event but stopped ther-
apy before the baseline survey was administered. The
true clinical indication for each drug therapy class
could not be assessed because blood pressure and
cholesterol levels were not captured in the SHIELD
survey. Thus, not all respondents may be candidates
for these drug therapies and contraindications or
intolerance of certain drugs could not be assessed.
Household panels, like the SHIELD study, tend to
under-represent the very wealthy and very poor seg-
ments of the population and do not include military
or institutionalised individuals.
Conclusions
Based on the study ﬁndings, treatment guidelines
have not been translated into practice for many
respondents in each risk group, including those with
prior or incident CVD events. There remains oppor-
tunity for signiﬁcant improvement in raising aware-
ness among physicians to put the recommended
therapy guidelines into practice and in motivating
at-risk individuals to seek preventive measures for
reducing CV disease, especially among respondents
with MI. Novel education programmes may be
required to increase the adoption of therapy guide-
lines among clinicians and their at-risk patients.
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